Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.4% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped 4.4% on Wednesday . The stock traded as low as $0.37 and last traded at $0.39. Approximately 78,251,078 shares were traded during trading, an increase of 160% from the average daily volume of 30,044,369 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock has a market capitalization of $69.15 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $0.22 and its 200 day moving average is $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.